OncoMatch/Clinical Trials/NCT06143631
Prescription of Letrozole for Uterine Myoma
Is NCT06143631 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Letrozole 2.5mg for leiomyoma, uterine.
Treatment: Letrozole 2.5mg — The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Cannot have received: surgery or radiologic procedure for leiomyomata
Leiomyomata treated by surgery, radiologic procedure in the last 12 weeks; or plans to undergo any of the above in the next 24 weeks
Cannot have received: GnRH agonist or antagonist
Leiomyomata treated by GRNH agonist or antagonist in the last 12 weeks; or plans to use the above in the next 24 weeks
Cannot have received: aromatase inhibitor (letrozole)
Use of letrozole, other aromatase inhibitor, or selective estrogen receptor modulator (SERM) medications in the past 4 weeks, or existing plans to initiate one of these in the next 24 weeks
Cannot have received: selective estrogen receptor modulator
Use of letrozole, other aromatase inhibitor, or selective estrogen receptor modulator (SERM) medications in the past 4 weeks, or existing plans to initiate one of these in the next 24 weeks
Cannot have received: exogenous estrogen, progestin, or androgen therapy
Use of oral, vaginal, or topical exogenous estrogen, progestin, or androgen therapy in the past 4 weeks; or injectable forms of the above in the past 12 weeks; or plans to initiate any of the above in the next 24 weeks
Cannot have received: medications with potential unsafe interactions with letrozole (methadone, levomethadone, nintedanib, thalidomide)
Use of medications with potential unsafe interactions with letrozole in the past 4 weeks (methadone, levomethadone, nintedanib, thalidomide), or plans to initiate these in the next 24 weeks
Lab requirements
Blood counts
Screening serum hemoglobin <8 g/dL, or history of blood transfusion in the last 12 weeks (indicating severe anemia)
Screening serum hemoglobin <8 g/dL, or history of blood transfusion in the last 12 weeks (indicating severe anemia)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Los Angeles · Los Angeles, California
- University of California, San Francisco · San Francisco, California
- Mayo Clinic · Rochester, Minnesota
- University of Mississippi Medical Center · Jackson, Mississippi
- Duke University · Durham, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06143631 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgery or radiologic procedure for leiomyomata, GnRH agonist or antagonist, aromatase inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 53 years or younger and at least 21 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify